Related Experiment Video

Updated: Nov 16, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

Severe Acute Respiratory Syndrome Coronavirus Type 2: Insight Into Challenges for Cell Therapy

Maryam Kaviani1, Negar Azarpira

  • 1From the Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation
|February 24, 2021
PubMed

Insights

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe illness and death. This review outlines critical aspects for managing SARS-CoV-2 infections within cell therapy protocols to ensure patient safety.

Area of Science:

  • Virology
  • Infectious Diseases
  • Cell Therapy

Background:

  • Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has led to a global health crisis.
  • The virus poses significant risks, including severe respiratory failure and mortality.
  • Cell therapy institutes require stringent protocols to mitigate infection risks.

Purpose of the Study:

  • To review essential considerations for integrating SARS-CoV-2 management into cell therapy protocols.
  • To highlight strategies for preventing and controlling viral spread in clinical settings.

Main Methods:

  • Literature review of scientific publications on SARS-CoV-2 and cell therapy.
  • Analysis of existing infection control measures relevant to immunocompromised patients.

Main Results:

  • Identification of key viral characteristics and transmission routes.
  • Discussion of challenges in maintaining sterile environments during cell therapy.
  • Outline of necessary modifications to standard operating procedures.

Conclusions:

  • Implementing specific SARS-CoV-2 protocols is crucial for cell therapy safety.
  • Proactive management strategies are essential to protect patients undergoing cell therapy.
  • Further research may be needed to optimize infection control in this vulnerable population.

More Related Videos

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

59.4K
Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro09:26

Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro

Published on: June 6, 2025

835

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
728
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
293
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
514